Date de Début
		01
		Jan 2021
	Statut
				
					Ongoing
				
	Membres
		
		5
	Structures
		
		5
	Publications
		
		3
	Financements
Références
- 
											
	2023Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma., Front Oncol 2023 ; 13(): 1110916.
- 
											
	2022The Sec61 translocon is a therapeutic vulnerability in multiple myeloma., EMBO Mol Med 2022 03; 14(3): e14740.
- 
											
	2018Proteomics reveals scope of mycolactone-mediated Sec61 blockade and distinctive stress signature, Mol. Cell Proteomics 2018 Jun;.
 
											 
											
 
											 
											 
											
 
													
 
													
